Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from MIRA Pharmaceuticals, Inc. ( (MIRA) ).
On June 30, 2025, MIRA Pharmaceuticals announced promising results from an animal study using SKNY-1, a drug candidate aimed at tackling obesity and nicotine cravings. The study demonstrated significant weight loss, appetite suppression, and reduced nicotine-seeking behavior in a zebrafish model, with improvements in metabolic activity and neurohormonal balance. These findings support the advancement of SKNY-1 toward further studies, positioning it as a potential key asset for MIRA in a market worth over $200 billion.
The most recent analyst rating on (MIRA) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on MIRA Pharmaceuticals, Inc. stock, see the MIRA Stock Forecast page.
More about MIRA Pharmaceuticals, Inc.
MIRA Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on developing next-generation oral therapeutics. The company is under a definitive agreement to acquire SKNY Pharmaceuticals, Inc., which aligns with its market focus on addressing obesity and smoking, two significant global health challenges.
Average Trading Volume: 1,240,626
Technical Sentiment Signal: Buy
See more data about MIRA stock on TipRanks’ Stock Analysis page.